NCT03323398: Dose Escalation Study of mRNA 2416 for Intratumoral Injection to Patients With Advanced Malignancies

NCT03323398
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Active central nervous system tumors or metastases
https://ClinicalTrials.gov/show/NCT03323398

Comments are closed.

Up ↑